Nexavar included in NICE's thyroid cancer recommendations

15 February 2018

Nexavar (sorafenib) is by no means Bayer’s (BAYN: DE) newest cancer drug but there is life in the blockbuster yet – as shown by a new recommendation from the National Institute for Health and Care Excellence (NICE).

Previously this drug was only available in England on the Cancer Drugs Fund for progressive, locally advanced or metastatic differentiated thyroid cancer in adults whose disease does not respond to radioactive iodine (RAI), despite the fact that it was approved by the European Medicines Agency in this indication in May 2014.

Now the NICE has made the drug available for routine funding on the National Health Service.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK